## Mersalyl

Cat. No.:	HY-108868	⁻HQ
CAS No.:	492-18-2	_∕Hg <sup>2</sup> ṫH₂ <sup>-</sup>
Molecular Formula:	C <sub>13</sub> H <sub>16</sub> HgNNaO <sub>6</sub>	0 → o
Molecular Weight:	505.85	N N
Target:	HIF/HIF Prolyl-Hydroxylase; VEGFR	
Pathway:	Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK	~ .0. H
Storage:	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)	O Na <sup>+</sup>

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (1	97.69 mM; Need ultrasonic)				
		Mass Solvent Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	1.9769 mL	9.8844 mL	19.7687 mL	
		5 mM	0.3954 mL	1.9769 mL	3.9537 mL	
		10 mM	0.1977 mL	0.9884 mL	1.9769 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution					
	2. Add each solvent Solubility: ≥ 2.5 m	one by one: 10% DMSO >> 90% (20 g/mL (4.94 mM); Clear solution	% SBE-β-CD in saline)			

BIOLOGICAL ACTIV	
Description	Mersalyl (Salirgan) is a potent vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects <sup>[1][2][3]</sup> .
In Vitro	Mersalyl (100 μM) induces VEGF and ENO1 mRNA expression but inhibits EPO mRNA expression induced by hypoxia, DFO, or CoCl2 <sup>[2]</sup> . Mersalyl (20 μM; 5 min) is a cell-impermeant organomercurial compound that reacts with free thiol groups in mitochondrial membrane protein <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCR <sup>[2]</sup>

Proteins

## Product Data Sheet



	Cell Line:	Hep3B cells
	Concentration:	100 µM
	Incubation Time:	6 h
	Result:	Induced VEGF and ENO1 mRNA expression but inhibited EPO mRNA expression induced by
		hypoxia, DFO, or CoCl2.
Vivo	Mersalyl (2.5-40 mg/kg; MCE has not independer	hypoxia, DFO, or CoCl2. intramuscularly injection) shows diuresis effects in Rats <sup>[3]</sup> . ntly confirmed the accuracy of these methods. They are for reference only.
Vivo	Mersalyl (2.5-40 mg/kg; MCE has not independer Animal Model:	hypoxia, DFO, or CoCl2. intramuscularly injection) shows diuresis effects in Rats <sup>[3]</sup> . ntly confirmed the accuracy of these methods. They are for reference only. Rats <sup>[3]</sup>
Vivo	Mersalyl (2.5-40 mg/kg; MCE has not independer Animal Model: Dosage:	hypoxia, DFO, or CoCl2. intramuscularly injection) shows diuresis effects in Rats <sup>[3]</sup> . ntly confirmed the accuracy of these methods. They are for reference only. Rats <sup>[3]</sup> 2.5-40 mg/kg
Vivo	Mersalyl (2.5-40 mg/kg; MCE has not independen Animal Model: Dosage: Administration:	hypoxia, DFO, or CoCl2.         intramuscularly injection) shows diuresis effects in Rats <sup>[3]</sup> .         ntly confirmed the accuracy of these methods. They are for reference only.         Rats <sup>[3]</sup> 2.5-40 mg/kg         Intramuscularly injection

## REFERENCES

[1]. Kowaltowski AJ, et al. Mitochondrial membrane protein thiol reactivity with N-ethylmaleimide or mersalyl is modified by Ca2+: correlation with mitochondrial permeability transition. Biochim Biophys Acta. 1997 Feb 15;1318(3):395-402.

[2]. Agani F, et al. Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol Pharmacol. 1998 Nov;54(5):749-54.

[3]. FARAH A, et al. Histochemical studies on the site of action of mercurial diuretics. J Histochem Cytochem. 1955 Jul;3(4):271-3.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA